Celldex Therapeutics Initiates Phase 2 Study of Barzolvolimab for Atopic Dermatitis Treatment

Quiver QuantitativeDec 19 08:14 ET

Celldex Launches Phase 2 Study Of Barzolvolimab For Atopic Dermatitis, Targeting Mast Cell-Driven Inflammation And Epithelial Barrier Dysfunction With Patient Enrollment Underway

BenzingaDec 19 08:12 ET

Express News | Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis

ReutersDec 19 08:01 ET

Celldex Therapeutics Initiates Phase 1a Trial for Bispecific Antibody CDX-622 Targeting Chronic Inflammation

Quiver QuantitativeNov 20 08:12 ET

Express News | Celldex Therapeutics Inc - Subcutaneous Formulation to Be Added to Study in 2025

ReutersNov 20 08:01 ET

Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases

GlobeNewswireNov 20 08:01 ET